For patients with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis, tirzepatide represents one of the most effective interventions currently available
She wrote that being vigilant for potential complications in the ever-changing landscape of systemic therapies is a duty toward patients and that the authors should be commended for their clinical observations and acting upon them. However, she recommended that these results should be interpreted with caution
For patients comparing options in the GLP-1 family, our tirzepatide 3-month weight loss guide can help set realistic expectations about progress over time
Join thousands of patients already seeing results
n = 4 (unstimulated, 14 day expanded) n = 3 (expanded to contraction)
Beyond GI: Pancreatitis, Gallbladder, and Thyroid Concerns Post-marketing surveillance has identified rare but serious concerns: acute pancreatitis, acute gallbladder disease, and reports of thyroid C-cell hyperplasia in animal studies